<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23463">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017613</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530-1301</org_study_id>
    <secondary_id>2013-003769-32</secondary_id>
    <nct_id>NCT02017613</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies</brief_title>
  <acronym>PI3K</acronym>
  <official_title>A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K
      delta/gamma inhibitor in patients with hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of RP6530 in patients with hematological malignancies</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To access maximum tolerated dose by clinical laboratory assessments, adverse events and dose limiting toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the Pharmacokinetics of RP6530</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameters AUC, Cmax, tmax, t1/2 will be determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical response following administration of RP6530 in patients with hematological malignancies</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess efficacy parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>RP6530</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP6530</intervention_name>
    <description>Escalating doses starting at 25 mg BID</description>
    <arm_group_label>RP6530</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory to or relapsed after at least 1 prior treatment line.

          -  ECOG performance status ≤2

          -  Patients must be ≥18 years of age

          -  Able to give a written informed consent.

        Exclusion Criteria:

          -  Any cancer therapy in the last 4 weeks or limited palliative radiation &lt;2 weeks

          -  Patients with HBV, HCV or HIV infection

          -  Autologous hematologic stem cell transplant within 3 months of study entry.
             Allogeneic hematologic stem cell transplant within 12 months.

          -  Previous therapy with GS-1101 (CAL-101, idelalisib), IPI-145, TGR-1202 or any drug
             that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus), AKT or
             BTK Inhibitor (including Ibrutinib).

          -  Patients on immunosuppressive therapy including systemic corticosteroids.

          -  Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium
             or heparin, etc.).

          -  Patients with known history of liver disorders.

          -  Patients with uncontrolled Diabetes Type I or Type II

          -  Any severe and/or uncontrolled medical conditions or other conditions that could
             affect their participation in the study.

          -  Women who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés J. M. Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Raffaele s.r.l.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Support</last_name>
    <phone>+41 32 580 0113</phone>
    <email>clinicaltrials@rhizen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rhizen Trial Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhizen Trial Site, Milano</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL, SLL, NHL, SLL, PTCL, CTCL, MM, AML</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
